NEGXF (NexgenRx) Cyclically Adjusted Revenue per Share: $0.15 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEGXF NexgenRx Inc NEGXF
40 GF Score
Price $0.33
GF Value $0.27
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is NexgenRx Cyclically Adjusted Revenue per Share?

NexgenRx NEGXF 40 Cyclically Adjusted Revenue per Share is $0.15 as of Mar. 2026. GuruFocus rates NEGXF with a GF Score™ of 40/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

NexgenRx's adjusted revenue per share for the three months ended in Mar. 2026 was $0.047. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.15 for the trailing ten years ended in Mar. 2026.

During the past 12 months, NexgenRx's average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of NexgenRx was 14.50% per year. The lowest was 9.10% per year. And the median was 11.05% per year.

As of today (2026-07-19), NexgenRx's current stock price is $0.325. NexgenRx's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.15. NexgenRx's Cyclically Adjusted PS Ratio of today is 2.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NexgenRx was 4.00. The lowest was 1.33. And the median was 2.39.


NexgenRx  (OTCPK:NEGXF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

NexgenRx's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.325/0.15
=2.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NexgenRx was 4.00. The lowest was 1.33. And the median was 2.39.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


NexgenRx Cyclically Adjusted Revenue per Share Related Terms


NexgenRx Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for NexgenRx's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexgenRx Cyclically Adjusted Revenue per Share Chart

NexgenRx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.10 0.13 0.12 0.13

NexgenRx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.09 0.09 0.13 0.15

NEGXF vs VEEV, BTSG, TEM: Cyclically Adjusted Revenue per Share Comparison

For the Health Information Services subindustry, NexgenRx's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NexgenRx Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NexgenRx's Cyclically Adjusted PS Ratio falls into.


NEGXF
40GF Score
NexgenRx Inc NEGXF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NexgenRx Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NexgenRx's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.047/132.2623*132.2623
=0.047

Current CPI (Mar. 2026) = 132.2623.

NexgenRx Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.027 102.002 0.035
201609 0.018 101.765 0.023
201612 0.017 101.449 0.022
201703 0.018 102.634 0.023
201706 0.018 103.029 0.023
201709 0.023 103.345 0.029
201712 0.017 103.345 0.022
201803 0.017 105.004 0.021
201806 0.017 105.557 0.021
201809 0.019 105.636 0.024
201812 0.027 105.399 0.034
201903 0.026 106.979 0.032
201906 0.025 107.690 0.031
201909 0.024 107.611 0.029
201912 0.028 107.769 0.034
202003 0.029 107.927 0.036
202006 0.026 108.401 0.032
202009 0.028 108.164 0.034
202012 0.028 108.559 0.034
202103 0.030 110.298 0.036
202106 0.030 111.720 0.036
202109 0.032 112.905 0.037
202112 0.035 113.774 0.041
202203 0.033 117.646 0.037
202206 0.035 120.806 0.038
202209 0.036 120.648 0.039
202212 0.035 120.964 0.038
202303 0.033 122.702 0.036
202306 0.037 124.203 0.039
202309 0.038 125.230 0.040
202312 0.038 125.072 0.040
202403 0.043 126.258 0.045
202406 0.041 127.522 0.043
202409 0.040 127.285 0.042
202412 0.039 127.364 0.040
202503 0.041 129.181 0.042
202506 0.045 129.892 0.046
202509 0.040 130.287 0.041
202512 0.042 130.366 0.043
202603 0.047 132.262 0.047

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.15 mean?
NexgenRx (NEGXF) has a Cyclically Adjusted Revenue per Share of $0.15 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on NexgenRx and its competitors.
Is NexgenRx's Cyclically Adjusted Revenue per Share too high?
NexgenRx's current Cyclically Adjusted Revenue per Share is $0.15. Overall, NexgenRx has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's Cyclically Adjusted Revenue per Share compare to VEEV and BTSG?
NexgenRx's Cyclically Adjusted Revenue per Share of $0.15 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Healthcare Providers & Services company?
A good Cyclically Adjusted Revenue per Share depends on the Healthcare Providers & Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on NexgenRx and its competitors. NexgenRx's current Cyclically Adjusted Revenue per Share is $0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.15. NexgenRx's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For NexgenRx (NEGXF), the current Cyclically Adjusted Revenue per Share is $0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NexgenRx (NEGXF) Overvalued in 2026?

Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued. The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27. GuruFocus considers NexgenRx to be Modestly Overvalued.

Key valuation signals for NEGXF:

  • Cyclically Adjusted Revenue per Share: $0.15
  • GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
  • GF Score™: 40/100 with 6 warning signs

No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NexgenRx Business Description

Other Exchanges NXG:Canada
Address 191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
40GF Score

Get the complete analysis for NEGXF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.27
GF Value